---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-009884"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:05:05.524559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tonix reports preliminary Q2 net operating loss of $26.3M, cash $125.3M, runway to Q3 2026

## Summary
- Net operating loss of $26.3M in Q2 2025, improved from $78.8M in Q2 2024.
- Cash and equivalents $125.3M at June 30; additional $50.6M raised in Q3 2025 equity offerings.
- Net cash used in ops $16.3M ($9.9M in Q2 2024); capex $1.1M (nil prior year).
- Revenue from marketed products $2.0M, down from $2.2M YoY.
- Company expects runway into Q3 2026; shares outstanding 8.7M as of July 25.

## SEC filing metadata
- accession: 0001999371-25-009884
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/0001999371-25-009884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125009884/tnxp-8k_072525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-009884
- JSON: https://secwatch.observer/filing/0001999371-25-009884.json
- Plain text: https://secwatch.observer/filing/0001999371-25-009884.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.